DOCSLIB.ORG

Serbian Archives of Medicine Journal of the Serbian Medical Society

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serbian Archives of Medicine Journal of the Serbian Medical Society SRP ARH CELOK LEK ISSN 0370-8179 (PRINT) COBISS.SR-ID 3378434 ISSN 2406-0895 (ONLINE) UDC 61(497.11) SERBIAN ARCHIVES OF MEDICINE JOURNAL OF THE SERBIAN MEDICAL SOCIETY VOLUME 149 • MAY–JUNE 2021 • ISSUE 5–6 www.srpskiarhiv.rs рпски архив за целокупно лекарство је часопис Српског лекарског друштва основаног 1872. године, први пут штампан 1874. године, у којем се објављују радови чланова Српског лекарског друштва, Спретплатника часописа и чланова других друштава медицинских и сродних струка. Објављују се: уводници, оригинални радови, претходна и кратка са- општења, прикази болесника и случајева, видео-чланци, слике из клиничке медицине, прегледни радови, актуелне теме, радови за праксу, радови из историје медицине и језика медицине, медицинске етике и регулаторних стандарда у медицини, извештаји са конгреса и научних скупова, лични ставови, наручени коментари, писма уреднику, прикази књига, стручне вести, In memoriam и други прилози. Сви рукописи који се разматрају за штампање у „Српском архиву за целокупно лекарство“ не могу да се поднесу или да буду разматрани за публиковање на другим местима. Радови не смеју да буду претходно штам- пани на другим местима (делимично или у потпуности). Приспели рукопис Уређивачки одбор шаље рецензентима ради стручне процене. Уколико рецензенти предложе измене или допуне, копија рецен- зије се доставља аутору с молбом да унесе тражене измене у текст рада или да аргументовано образложи своје неслагање с примедбама рецензента. Коначну одлуку о прихватању рада за штампу доноси главни и одговорни уредник. За објављене радове се не исплаћује хонорар, а ауторска права се пре- носе на издавача. Рукописи и прилози се не враћају. За репродукцију или поновно објављивање неког сегмента рада публикованог у „Српском ар- хиву“ неопходна је сагласност издавача. Радови се штампају на енглеском језику са кратким садржајем на ен- глеском и српском језику (ћирилица), односно на српском језику, са крат- ким садржајем на српском и енглеском језику. Аутори прихватају потпуну одговорност за тачност целокупног садр- жаја рукописа. Материјал публикације представља мишљење аутора и није нужно одраз мишљења Српског лекарског друштва. С обзиром на брз напредак медицинске научне области, корисници треба да независно Прва страна првог броја часописа на српском језику процењују информацију пре него што је користе или се на њу ослањају. Српско лекарско друштво, уредник или Уређивачки одбор „Српског ар- хива за целокупно лекарство“ не прихватају било какву одговорност за наводе у радовима. Рекламни материјал треба да буде у складу с етичким (медицинским) и правним стандардима. Рекламни материјал укључен у овај часопис не гарантује квалитет или вредност оглашеног производа, односно тврдње произвођача. Поднесени рукопис подразумева да је његово публиковање одобрио одговорни ауторитет установе у којој је истраживање обављено. Издавач се неће сматрати правно одговорним у случају подношења било каквог захтева за компензацију. Треба да се наведу сви извори финансирања рада. rpski Arhiv Za Celokupno Lekarstvo (Serbian Archives of Medicine) is the Journal of the Serbian Medical Society founded in 1872, and with first issue published in 1874. Serbian Archives of Medicine publishes articles of Sthe Serbian Medical Society members, subscribers, as well as members of other associations of medical and related fields. The journal publishes the following article types: editorials, original papers, preliminary and short communications, case reports, video-articles, images in clinical medicine, review articles, current topics, articles for practitioners, history of medicine articles, language of medi- cine articles, medical ethics (clinical ethics, publication ethics) and regulatory standards in medicine, congress and scientific meeting reports, personal view articles, invited commentaries, letters to the editor, book reviews, professional news, In memoriam and other articles. All manuscripts under consideration in the Serbian Archives of Medicine may not be offered or be under consideration for publication elsewhere. Articles must not have been published elsewhere (in part or in full). The submitted manuscripts are forwarded by the Editorial Board to reviewers for editing and evaluation. If the reviewers find that the manuscript needs to be modified or amended, the copy of the report is sent to the author(s), requiring of them to make necessary modifications or amendments of the text or to provide argumentative explanation of their disagreement with the suggested reviewer’s remarks. The final decision on acceptance of the article for publication is made by the Editor-in-Chief. The authors shall not be remunerated for the published articles, and they are required to assign copyright of their papers to the publisher. Manuscripts and enclosures shall not be returned to the authors. Reproduction or repeated publication of any section of the manuscript already published in the “Serbian Archives” requires the publisher’s approval. The articles are printed in the English language with an abstract both in English and Serbian, or in the Serbian language, Cyrillic alphabet, with an ab- stract in Serbian and English. Authors accept full responsibility for the accuracy of all content within the manuscript. Material in the publication represents the opinions of the authors and does not necessarily reflect opinions of the Serbian Medical Society. Because The title page of the first journal volume in Latin of rapid advances in the medical sciences, users should independently evaluate information before using or relying on it. Serbian Medical Society, the Editor or Editorial Board of the Serbian Archives of Medicine do not accept any re- sponsibility for the statements in the articles. Advertising material is expected to conform to ethical (medical) and legal standards. Inclusion of advertising material in this publication does not guarantee the quality or value of such product or claims made by its manufacturer. Submission of the manuscript implies that its publication has been approved by the responsible authorities at the institution where the work has been carried out. The publisher will not be held legally responsible should be any claims for compensation. Details of all funding sources for the work should be given. Srp Arh Celok Lek ISSN 0370-8179 UDC 61(497.11) COBISS.SR-ID 3378434 Српски архив за целокупно лекарство Званичан часопис Српског лекарског друштва С РПСКИ АРХИВ ЗА ЦЕЛОКУПНО ЛЕКАРСТВО Излази шест пута годишње ГОДИШТЕ 149. МАЈ–ЈУН 2021. СВЕСКА 5–6 Часопис „Српски архив за целокупно лекарство“ је индексиран у базама: Science Citation Index Expanded, Journal Citation Reports/Science Edition, Web of Science, Scopus, EBSCO, Directory of Open Access Journals, DOI Serbia. ОСНИВАЧ, ВЛАСНИК И ИЗДАВАЧ Српско лекарско друштво ГЛАВНИ И ОДГОВОРНИ УРЕДНИК Проф. др Татјана Симић, дописни члан САНУ Џорџа Вашингтона 19, 11000 Београд, Србија Проф. др Гордана Теофиловски-Парапид Проф. др Мирослав Стаменковић Председник Проф. др Горан Стевановић Проф. др Едита Стокић Академик Радоје Чоловић ЗАМЕНИК ГЛАВНОГ И ОДГОВОРНОГ УРЕДНИКА Интернет страна: http://www.sld.org.rs Академик Миодраг Чолић Проф. др Павле Миленковић Проф. др Сњежана Чолић ИЗДАВАЧКИ САВЕТ ПОМОЋНИЦИ ГЛАВНОГ МЕЂУНАРОДНИ УРЕЂИВАЧКИ ОДБОР Проф. др Павле Миленковић, председник И ОДГОВОРНОГ УРЕДНИКА Prof. dr Achilles Anagnostopoulos (Грчка) Академик Владимир Бумбаширевић Проф. др Татјана Илле Prof. dr Athanassios Athanassiou (Грчка) Проф. др Љубица Ђукановић Проф. др Недељко Радловић Prof. dr Henry Dushan Edward Atkinson Академик Небојша Лалић Проф. др Драгослав Стаменковић (Велика Британија) Проф. др Милица Чоловић Prof. dr Sheryl Avery (Велика Британија) УРЕЂИВАЧКИ ОДБОР Prof. dr Alastair Forbes (Велика Британија) Prof. dr Mila Goldner-Vukov (Аустралија) Проф. др Горан Белојевић АДРЕСА УРЕДНИШТВА Prof. dr Nagy Habib (Велика Британија) Проф. др Марко Бумбаширевић, дописни Српски архив Prof. dr Richard John (Bill) Heald члан САНУ Краљице Наталије 1, 11000 Београд, Србија (Велика Британија) Проф. др Мирослава Гојнић-Дугалић Телефон: +381 (0)11 409 27 76 Prof. dr Rajko Igić (САД) Проф. др Мирјана Готић +381 (0)11 409 44 79 Prof. dr Dorothy Keefe (Аустралија) Проф. др Златан Елек Е-пошта: [email protected] Prof. dr Stanislaw Klek (Пољска) Проф. др Иван Јовановић Интернет страна: www.srpskiarhiv.rs Prof. dr Bernhard Maisch (Немачка) Проф. др Тања Јовановић Prof. dr Masatoshi Makuchi (Јапан) Академик Владимир Костић Prof. dr Gordana Matijašević-Cavrić (Боцвана) Проф. др Гордана Коцић ПРЕТПЛАТА И ЕКСПЕДИЦИЈА Prof. dr Veselin Mitrović (Немачка) Академик Зоран Кривокапић Српско лекарско друштво Prof. dr Akimasa Nakao, MD, PhD, FACS (Јапан) Проф. др Душан Лалошевић Џорџа Вашингтона 19, 11000 Београд, Србија Prof. dr Ljupčo T. Nikolovski (Македонија) Академик Душица Лечић-Тошевски Телефон: +381(0)11 3245-149 Prof. dr Philip B. Paty (САД) Проф. др Наташа Максимовић Текући рачуни: 205-8041-21 и Prof. dr Dan V. Poenaru (Румунија) Проф. др Јовица Миловановић 355-1009094-22 Prof. dr Igor Vladimirovich Reshetov (Русија) Проф. др Марјан Мицев Prof. dr Manuel Sobrinho Simões (Португал) Проф. др Биљана Обреновић-Кирћански Prof. dr Tatjana Stanković-Taylor Научни саветник Соња Павловић Чланци у целости доступни су на интернет (Велика Британија) Проф. др Милета Поскурица страници: www.srpskiarhiv.rs Prof. dr Vladan Starčević (Аустралија) Проф. др Арсен Ристић Prof. dr Igor Švab (Словенија) Проф. др Горица Ристић Prof. dr A. Malcolm R. Taylor Проф. др Александар Савић (Велика Британија) Проф. др Марина Светел
Load more

Recommended publications
  • Multifaceted Physiological Roles of Adiponectin in Inflammation And
    International Journal of Molecular Sciences Review Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases Hyung Muk Choi 1, Hari Madhuri Doss 1,2 and Kyoung Soo Kim 1,2,* 1 Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul 02447, Korea; [email protected] (H.M.C.); [email protected] (H.M.D.) 2 East-West Bone & Joint Disease Research Institute, Kyung Hee University Hospital at Gangdong, Gandong-gu, Seoul 02447, Korea * Correspondence: [email protected]; Tel.: +82-2-961-9619 Received: 3 January 2020; Accepted: 10 February 2020; Published: 12 February 2020 Abstract: Adiponectin is the richest adipokine in human plasma, and it is mainly secreted from white adipose tissue. Adiponectin circulates in blood as high-molecular, middle-molecular, and low-molecular weight isoforms. Numerous studies have demonstrated its insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects. Additionally, decreased serum levels of adiponectin is associated with chronic inflammation of metabolic disorders including Type 2 diabetes, obesity, and atherosclerosis. However, recent studies showed that adiponectin could have pro-inflammatory roles in patients with autoimmune diseases. In particular, its high serum level was positively associated with inflammation severity and pathological progression in rheumatoid arthritis, chronic kidney disease, and inflammatory bowel disease. Thus, adiponectin seems to have both pro-inflammatory and anti-inflammatory effects. This indirectly indicates that adiponectin has different physiological roles according to an isoform and effector tissue. Knowledge on the specific functions of isoforms would help develop potential anti-inflammatory therapeutics to target specific adiponectin isoforms against metabolic disorders and autoimmune diseases.
    [Show full text]
  • Adiporon, an Orally Active, Synthetic Agonist of Adipor1 and Adipor2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice
    molecules Article AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice Hubert Zatorski 1,2, Maciej Salaga 1 , Marta Zieli ´nska 1, Kinga Majchrzak 1, Agata Binienda 1 , Radzisław Kordek 3, Ewa Małecka-Panas 2 and Jakub Fichna 1,4,* 1 Department of Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] (H.Z.); [email protected] (M.S.); [email protected] (M.Z.); [email protected] (K.M.); [email protected] (A.B.) 2 Department of Digestive Tract Diseases, Medical University of Lodz, 93-281 Lodz, Poland; [email protected] 3 Department of Pathology, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] 4 Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland * Correspondence: jakub.fi[email protected]; Tel.: +48-42-272-57-07 Citation: Zatorski, H.; Salaga, M.; Abstract: Introduction: Adiponectin is a hormone secreted by adipocytes, which exhibits insulin- Zieli´nska,M.; Majchrzak, K.; sensitizing and anti-inflammatory properties and acts through adiponectin receptors: AdipoR1 and Binienda, A.; Kordek, R.; AdipoR2. The aim of the study was to evaluate whether activation of adiponectin receptors AdipoR1 Małecka-Panas, E.; Fichna, J. and AdipoR2 with an orally active agonist AdipoRon has gastroprotective effect and to investigate AdipoRon, an Orally Active, the possible underlying mechanism. Methods: We used two well-established mouse models of Synthetic Agonist of AdipoR1 and gastric ulcer (GU) induced by oral administration of EtOH (80% solution in water) or diclofenac AdipoR2 Receptors Has (30 mg/kg, p.o.).
    [Show full text]
  • Axon Medchem
    Understanding Communication Satisfaction “Together we are stronger!” Axon Medchem - A top-line chemistry service platform specialized in contract research in medicinal chemistry and Contract Research Organization high-quality synthesis of bio-active and/or drug-like molecules. in Medicinal Chemistry Providing Axon Ligands™ for Pharmaceutical Research - Proven track record in developing novel drug candidates and achieving excellence for a decade by collaborating with partners and serving research scientists all over the world. Prime Source High Value - Prime source of highest performance and up-to-date life science reagents, providing Axon High Quality Ligands™ for advanced pharmaceutical research. Axon Ligands™ - Reagents for over 500 Biological Targets - A unique collection of biologically active molecules, as world-wide recognized research tools and drug standards in diversified application fields such as neurological disorders, cardiovascular Axon Medchem BV The Netherlands disease, pain and inflammation, epigenetics, stem cell biology, apoptosis and many more on cell Tel: +31-50-3118007 signaling and oncology research. Fax: +31-50-3600390 [email protected] - Featured products with our expertise including CNS reagents, ion channel modulators, signal transduction regulators (such as kinase inhibitors) and much more … Axon Medchem LLC USA Axon Ligands™ are widely used by research institutes and Axon Medchem has been cited in Tel: (888) 703-9861 numerous publications as their supplier of drugs. Fax: (703) 596-8062 [email protected]
    [Show full text]
  • Adipor Agonist Increases Insulin Sensitivity and Exercise Endurance
    ARTICLE https://doi.org/10.1038/s42003-020-01579-9 OPEN AdipoR agonist increases insulin sensitivity and exercise endurance in AdipoR-humanized mice ✉ Masato Iwabu1,2,3,11, Miki Okada-Iwabu 1,3,11 , Hiroaki Tanabe 4,5, Nozomi Ohuchi1, Keiko Miyata1, ✉ Toshiko Kobori6, Sara Odawara1, Yuri Kadowaki1, Shigeyuki Yokoyama 4,5, Toshimasa Yamauchi 1,7 & ✉ Takashi Kadowaki 1,8,9,10 1234567890():,; Adiponectin receptors, AdipoR1 and AdipoR2 exert anti-diabetic effects. Although muscle- specific disruption of AdipoR1 has been shown to result in decreased insulin sensitivity and decreased exercise endurance, it remains to be determined whether upregulation of AdipoR1 could reverse them in obese diabetic mice. Here, we show that muscle-specific expression of human AdipoR1 increased expression levels of genes involved in mitochondrial biogenesis and oxidative stress-detoxification to almost the same extents as treadmill exercise, and concomitantly increased insulin sensitivity and exercise endurance in obese diabetic mice. Moreover, we created AdipoR-humanized mice which express human AdipoR1 in muscle of AdipoR1·R2 double-knockout mice. Most importantly, the small-molecule AdipoR agonist AdipoRon could exert its beneficial effects in muscle via human AdipoR, and increased insulin sensitivity and exercise endurance in AdipoR-humanized mice. This study suggests that expression of human AdipoR1 in skeletal muscle could be exercise-mimetics, and that Adi- poRon could exert its beneficial effects via human AdipoR1. 1 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. 2 PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.
    [Show full text]
  • Insulin Action/Molecular Metabolism
    INSULIN ACTION—ADIPOCYTECATEGORY BIOLOGY 1692-P 1694-P Stress in Beta Cells Obtained with Laser Capture Microdissection Biopsy-Proven Insulitis of Clinical Islet Transplantation Is Not from Cadaver Pancreases of Brain Dead Donors Reversed by Steroid Therapy AREF EBRAHIMI, MIN-HO JUNG, JONATHAN M. DREYFUSS, HUI PAN, DENNIS ANNA LAM, BEHRUZ RAHIMI, SHARLEEN IMES, KIM SOLEZ, JAMES SHAPIRO, C. SGROI, SUSAN BONNER-WEIR, GORDON C. WEIR, Boston, MA PETER A. SENIOR, Edmonton, AB, Canada Brain death of pancreas donors is thought to lead to the expression of Gradual decline in islet function remains a challenge in clinical islet infl ammatory, stress and apoptotic pathways in isolated islets resulting in transplantation (CIT), but acute graft loss is relatively uncommon. Here we poor clinical outcomes. To test this hypothesis we obtained cadaveric pan- describe a case of acute decline in graft function with histology suggesting creases from brain dead pancreatic donors (n=7, mean age 5011) and normal an immune mechanism. A 49 year old female (BMI 24.4 kg/m2, insulin 0.3 pancreatic tissue obtained at surgery done for pancreatic neoplasms (n=7, U/kg) with type 1 diabetes for 37 years underwent two CIT (6071 and 6827 age 699). Frozen sections were subjected to laser capture microdissection islet equivalents/kg) following alemtuzumab induction with tacrolimus (TAC, to obtain beta-cell rich islet tissue, from which extracted RNA was analyzed mean 8 ug/L) and mycophenolate mofetil for maintenance. Initial engraft- with Affymetrix arrays. Gene expression of the two groups was evaluated ment was reasonable (β2 score of 12 at 1 week), but β2 score gradually with principle component analysis (PCA), and differential expression anal- declined (Figure 1) rising to 19 after the second CIT.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Adiporon Treatment Induces a Dose-Dependent Response in Adult Hippocampal Neurogenesis
    International Journal of Molecular Sciences Article AdipoRon Treatment Induces a Dose-Dependent Response in Adult Hippocampal Neurogenesis Thomas H. Lee 1 , Brian R. Christie 2 , Henriette van Praag 3, Kangguang Lin 4, Parco Ming-Fai Siu 5, Aimin Xu 6,7,8, Kwok-Fai So 9,10,11 and Suk-yu Yau 1,* 1 Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong; [email protected] 2 Division of Biomedical Sciences, University of Victoria, Victoria, BC V8P 5C2, Canada; [email protected] 3 FAU Brain Institute and Charles E. Schmidt College of Medicine, Florida Atlantic University, Jupiter, FL 33431, USA; [email protected] 4 Department of Affective Disorder, Guangzhou Brain Hospital, The Brain Affiliated Hospital of Guangzhou Medical University, Guangzhou 510370, China; [email protected] 5 Division of Kinesiology, School of Public Health, The University of Hong Kong, Hong Kong; [email protected] 6 Department of Medicine, The University of Hong Kong, Hong Kong; [email protected] 7 Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong 8 The State Key Laboratory of Pharmacology, The University of Hong Kong, Hong Kong 9 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China; [email protected] 10 State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong 11 Department of Ophthalmology, The University of Hong Kong, Hong Kong * Correspondence: [email protected]; Tel.: +852-2766-4890 Abstract: AdipoRon, an adiponectin receptor agonist, elicits similar antidiabetic, anti-atherogenic, Citation: Lee, T.H.; Christie, B.R.; and anti-inflammatory effects on mouse models as adiponectin does.
    [Show full text]
  • Obesity Reduces the Anticancer Effect of Adiporon Against Orthotopic
    www.nature.com/scientificreports OPEN Obesity reduces the anticancer efect of AdipoRon against orthotopic pancreatic cancer in diet‑induced obese mice Keizo Takenaga1*, Miho Akimoto2, Nobuko Koshikawa1 & Hiroki Nagase1 The antidiabetic adiponectin receptor agonist AdipoRon has been shown to suppress the tumour growth of human pancreatic cancer cells. Because obesity and diabetes afect pancreatic cancer progression and chemoresistance, we investigated the efect of AdipoRon on orthotopic tumour growth of Panc02 pancreatic cancer cells in DIO (diet‑induced obese) prediabetic mice. Administration of AdipoRon into DIO mice fed high‑fat diets, in which prediabetic conditions were alleviated to some extent, did not reduce either body weight or tumour growth. However, when the DIO mice were fed low‑fat diets, body weight and the blood leptin level gradually decreased, and importantly, AdipoRon became efective in suppressing tumour growth, which was accompanied by increases in necrotic areas and decreases in Ki67‑positive cells and tumour microvessels. AdipoRon inhibited cell growth and induced necrotic cell death of Panc02 cells and suppressed angiogenesis of endothelial MSS31 cells. Insulin and IGF‑1 only slightly reversed the AdipoRon‑induced suppression of Panc02 cell survival but had no efect on the AdipoRon‑induced suppression of MSS31 cell angiogenesis. Leptin signifcantly ameliorated AdipoRon‑induced suppression of angiogenesis through inhibition of ERK1/2 activation. These results suggest that obesity‑associated factors weaken the anticancer efect of AdipoRon, which indicates the importance of weight loss in combating pancreatic cancer. Pancreatic cancer is the most lethal cancer. Most of the tumours are already unresectable at diagnosis, and the 5-year survival rate is quite low1.
    [Show full text]
  • Small Molecule of Adiponectin Receptor Agonist— Adiporon—For Alzheimer Disease: Abridged Secondary Publication RCL Ng *, M Jian, M Bunting, SK Chung, KH Chan
    HEALTH AND MEDICAL RESEARCH FUND Small molecule of adiponectin receptor agonist— AdipoRon—for Alzheimer disease: abridged secondary publication RCL Ng *, M Jian, M Bunting, SK Chung, KH Chan KEY MESSAGES protective effects to neurons and synapses in Alzheimer mouse model. 1. Chronic oral administration of AdipoRon reverses spatial learning and memory performance in an Alzheimer mouse model. Hong Kong Med J 2020;26(Suppl 7):S29-32 2. AdipoRon crosses the blood-brain barrier and HMRF project number: 03143856 reaches maximum concentration 2 hours after 1 RCL Ng, 1 M Jian, 1 M Bunting, 2 SK Chung, 1 KH Chan oral administration. 3. AdipoRon enhances neuronal insulin sensitivity LKS Faculty of Medicine, The University of Hong Kong: 1 and reduces amyloid-β deposition. Department of Medicine 2 School of Biomedical Sciences 4. AdipoRon suppresses amyloid-β-mediated neuroinflammatory responses, exerting* Principal applicant and corresponding author: [email protected] Introduction in AD-like pathologies and cognitive impairments in aged mice, and these mice develop cerebral Alzheimer disease (AD) is the most common insulin resistance with reduced hippocampal neurodegenerative cause leading to dementia. insulin sensitivity.2 AdipoRon is a newly invented The characteristic neuropathological features of adiponectin receptor agonist that can be orally AD include amyloid-β-forming neuritic plaques, administered. It can improve glucose uptake, lipid hyperphosphorylated tau-forming intracellular metabolism, and insulin sensitivity in mammalian neurofibrillary tangles, neuroinflammation, andcells and in mice. Life span has been increased in neuronal loss in the hippocampus and frontal high-fat-diet-fed db/db mice (an animal model cortex. In AD drug invention, immunotherapy- for type 2 diabetes mellitus and obesity) through based targeting amyloid-β and tau treatment metabolic improvement after oral administrating have demonstrated promising results in mouse AdipoRon.
    [Show full text]
  • Orally Active Compound Library (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
    [Show full text]
  • Inhibitors & Agonists Compound Screening Libraries
    www.MedChemExpress.com MedChemExpress Inhibitors & Agonists 25,000+ Specific Inhibitors & Agonists Targeting 20+ Classic Signaling Pathways Compound Screening Libraries 50+ Compound Screening Libraries Optimized for Disease Mechanism Revealing & Drug Repurposing Nature. 2020 Apr;580(7803):386-390. Cell. 2020 Apr 6. pii: S0092-8674(20)30268-3. Cell. 2020 Mar 5;180(5):941-955.e20. Nature. 2020 Mar;579(7799):433-437. Science. 2020 Feb 14;367(6479):806-810. Cell. 2020 Feb 20;180(4):645-654.e13. Nature. 2019 Dec;576(7786):274-280. Cell. 2019 Dec 12;179(7):1483-1498.e22. Cell. 2019 Dec 12;179(7):1566-1581.e16. Nature. 2019 Nov;575(7782):375-379. Nature. 2019 Nov;575(7784):683-687. Nature. 2019 Oct;574(7777):264-267. Cell. 2019 Oct 31;179(4):864-879.e19. Nat Nanotechnol. 2019 Oct;14(10):988-993. Publications Citing Use of MCE Products Citing Use of Publications Nat Biotechnol. 2019 Oct;37(10):1209-1216. Cell. 2019 Aug 22;178(5):1145-1158.e20. Cell. 2019 Aug 22;178(5):1132-1144.e10. Nature. 2019 Jul;571(7763):127-131. Science. 2019 Jul 19;365(6450). Cell. 2019 Jul 25;178(3):585-599.e15. Cell. 2019 Jul 11;178(2):330-345.e22. Inhibitors & Agonists “ 25,000+ selective Inhibitors and Agonists We offer Targeting 375 key proteins in 20+ signaling pathways only the Applications in different disease areas highest- Screening Libraries grade MCE Compound Screening Libraries consist of 10,000+ small molecules with products! validated biological and pharmacological activities Quality Our robust quality control methods assure product high quality and purity.
    [Show full text]
  • EASD2020 Finalprogramme.Pdf
    56TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES Content Page EASD . 4 Morgagni Prize . 10 General Information . 12 EASD Community Plaza . 15 Programme at a Glance . 20 EASD e-Learning . 28 European Diabetes Forum (EUDF) . 29 EFSD Mentorship Programme . 30 Tuesday, 22 September . 32 Claude Bernard Lecture . 32 Poster Event A . 41 Poster Event B . 42 Camillo Golgi Lecture . 50 Albert Renold Lecture . 52 Wednesday, 23 September . 54 Poster Event C . 64 Poster Event D . 65 Diabetes Prize for Excellence Lecture . 72 Thursday, 24 September . 77 Rising Star Symposium . 80 Poster Event E . 90 Poster Event F . 91 Minkowski Lecture . 98 Friday, 25 September . 102 Posters . 119 Index of Presenting Authors . 230 Index of Symposium Speakers . 242 European Foundation for the Study of Diabetes (EFSD) . 244 Symposia on the occasion of the 56th EASD Annual Meeting . 248 Industry Symposia and Meet the Expert Sessions on the occasion of the 56th EASD Annual Meeting (organised by INTERPLAN) . 263 57th EASD Annual Meeting . 310 DEAR MEMBERS AND GUESTS, It is my great honour and pleasure to welcome you to the 56th Annual Meeting of the European Association for the Study of Diabetes, which will take place – due to the severe global impact of the COVID-19 pandemic – as an innovative Virtual Meeting from 21 to 25 September 2020. EASD We have developed a virtual experience using the latest technology to connect the global diabetes community, share ground-breaking diabetes science and research, and to provide educational opportunities that
    [Show full text]